The role of radiotherapy for T4 non-melanoma skin carcinoma

Matthiesen, Chance; Thompson, John S.; Forest, Christina; Ahmad, Salahuddin; Herman, Terence; Bogardus, Carl R.

doi:10.1111/j.1754-9485.2011.02277.x

Cited by 14 publications

(20 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…18 We found five studies including 191 patients that reported deaths as a result of SCC, 547,585,[588][589][590] with an average of 9.1% of patients dying from their disease on pooled analysis (95% CI 1.4% to 22.8%; I 2 = 79%) 23,67,[70][71][72] ( Figure 43). The greatest proportion of deaths was observed in a study of advanced T4 tumours in which two of three patients with eligible SCCs died (66%, 95% CI 9.4% to 99.1%) 590 during a mean follow-up period of 14 months. For studies with mean duration of follow-up between 2 and 5 years, the average recurrence was 4.8% (119 patients, 95% CI 1.6% to 9.8%).…”

Section: Squamous Cell Skin Cancer Work Programmementioning

confidence: 99%

“…However, the number of patients was very small (n = 5) and, in one of the studies, 590 only T4 tumours were treated with recurrence in two out of three patients. Average recurrence in the two studies with specified mean duration of follow-up of between 2 and 5 years was 6.1% (44 patients, 95% CI 0% to 22.6%).…”

Section: Squamous Cell Skin Cancer Work Programmementioning

confidence: 99%

“…542,547,554,[581][582][583][584][585][586][587][588][589][590][591] Seven studies (comprising 761 patients) reported local recurrence after external radiotherapy, with pooled average local recurrence of 6.4% (95% CI 3.0% to 11.0%; I 2 = 76%) 542,547,581,582,584,585,591 (see Appendix 8 and Figure 40). Three studies were included in the sensitivity analysis, 582,585,591 with no significant effect on local recurrence (7.3%, 95% CI 2.1% to 15.4%; I 2 = 87%).…”

Section: External Radiotherapymentioning

confidence: 99%

“…554,583,[587][588][589][590] Pooled data from the 220 treated SCCs from the studies gave an average recurrence of 4.8% (95% CI 0.6% to 12.8%; I 2 = 70%) ( Figure 42).…”

Section: Squamous Cell Skin Cancer Work Programmementioning

confidence: 99%

“…Two of the studies 583,590 had a mean duration of follow-up of < 2 years with pooled recurrence of 27.2% (95% CI 2.0% to 89%). However, the number of patients was very small (n = 5) and, in one of the studies, 590 only T4 tumours were treated with recurrence in two out of three patients.…”

Section: Squamous Cell Skin Cancer Work Programmementioning

confidence: 99%

See 4 more Smart Citations

A programme of research to set priorities and reduce uncertainties for the prevention and treatment of skin disease

Kim

Batchelor

Bath‐Hextall

et al. 2016

Programme Grants Appl Res

View full text Add to dashboard Cite

Programme Grants for Applied ResearchISSN 2050-4322 (Print) ISSN 2050-4330 (Online) This journal is a member of and subscribes to the principles of the Committee on Publication Ethics (COPE) (www.publicationethics.org/).Editorial contact: nihredit@southampton.ac.ukThe full PGfAR archive is freely available to view online at www.journalslibrary.nihr.ac.uk/pgfar. Print-on-demand copies can be purchased from the report pages of the NIHR Journals Library website: www.journalslibrary.nihr.ac.uk Criteria for inclusion in the Programme Grants for Applied Research journalReports are published in Programme Grants for Applied Research (PGfAR) if (1) they have resulted from work for the PGfAR programme, and (2) they are of a sufficiently high scientific quality as assessed by the reviewers and editors. Programme Grants for Applied Research programmeThe Programme Grants for Applied Research (PGfAR) programme, part of the National Institute for Health Research (NIHR), was set up in 2006 to produce independent research findings that will have practical application for the benefit of patients and the NHS in the relatively near future. The Programme is managed by the NIHR Central Commissioning Facility (CCF) with strategic input from the Programme Director.The programme is a national response mode funding scheme that aims to provide evidence to improve health outcomes in England through promotion of health, prevention of ill health, and optimal disease management (including safety and quality), with particular emphasis on conditions causing significant disease burden.For more information about the PGfAR programme please visit the website: http://www.nihr.ac.uk/funding/programme-grants-forapplied-research.htm This reportThe research reported in this issue of the journal was funded by PGfAR as project number RP-PG-0407-10177. The contractual start date was in September 2008. The final report began editorial review in April 2014 and was accepted for publication in April 2016. As the funder, the PGfAR programme agreed the research questions and study designs in advance with the investigators. The authors have been wholly responsible for all data collection, analysis and interpretation, and for writing up their work. The PGfAR editors and production house have tried to ensure the accuracy of the authors' report and would like to thank the reviewers for their constructive comments on the final report document. However, they do not accept liability for damages or losses arising from material published in this report.This report presents independent research funded by the National Institute for Health Research (NIHR). The views and opinions expressed by authors in this publication are those of the authors and do not necessarily reflect those of the NHS, the NIHR, CCF, NETSCC, PGfAR or the Department of Health. If there are verbatim quotations included in this publication the views and opinions expressed by the interviewees are those of the interviewees and do not necessarily reflect those of the authors, those of the NHS, the NIHR, ...

show abstract

Section: Squamous Cell Skin Cancer Work Programmementioning

confidence: 99%

Section: Squamous Cell Skin Cancer Work Programmementioning

confidence: 99%

Section: External Radiotherapymentioning

confidence: 99%

“…554,583,[587][588][589][590] Pooled data from the 220 treated SCCs from the studies gave an average recurrence of 4.8% (95% CI 0.6% to 12.8%; I 2 = 70%) ( Figure 42).…”

Section: Squamous Cell Skin Cancer Work Programmementioning

confidence: 99%

Section: Squamous Cell Skin Cancer Work Programmementioning

confidence: 99%

See 3 more Smart Citations

A programme of research to set priorities and reduce uncertainties for the prevention and treatment of skin disease

Kim

Batchelor

Bath‐Hextall

et al. 2016

Programme Grants Appl Res

View full text Add to dashboard Cite

show abstract

Principles of Radiotherapy

Kelly

Frew

2016

Rook's Textbook of Dermatology, Ninth Edition

View full text Add to dashboard Cite

The clinical effects of ionizing radiation on the skin have been known since the discovery of X‐rays in 1895. Initially, both benign and malignant skin conditions were irradiated, and dose and clinical indications were chosen empirically with little knowledge of the late effects of radiation on the skin and subcutaneous tissue. Indications for treating benign disease by irradiation have declined since the advent of topical steroids. It is in the best interest of patients suffering from skin tumours to be seen in a clinic where the expertise of specialists in radiotherapy and oncology, plastic surgery and micrographic surgery as well as dermatology are present. This is being achieved with the mandatory development of multidisciplinary team meetings and clinics in the UK as described in the National Institute for Health and Care Excellence guidelines of 2006.

show abstract

Principles of Radiotherapy

Kelly,

Frew,

Mahtab

2024

Rook's Textbook of Dermatology

View full text Add to dashboard Cite

Radiotherapy has been used for over a century to treat skin malignancies and still has a curative role to play in a number of different skin pathologies, as well as in adjuvant and palliative settings and where lack of patient fitness or reserve precludes extensive surgery. It is also finding new roles, as in its use in stereotactic radiosurgery for melanoma brain metastases. The potential uses of radiotherapy provide additional options within the multidisciplinary skin cancer team meeting and helps optimise individual skin cancer management plans. Its use is not without morbidities, whose management have also to be considered.

show abstract

The role of radiotherapy for T4 non-melanoma skin carcinoma

Cited by 14 publications

References 16 publications

A programme of research to set priorities and reduce uncertainties for the prevention and treatment of skin disease

A programme of research to set priorities and reduce uncertainties for the prevention and treatment of skin disease

Principles of Radiotherapy

Principles of Radiotherapy

Contact Info

Product

Resources

About